Key facts
- This page summarizes William Todd Horich's Form 4 filing for Supernus, Inc. (INDV).
- 18 reported transactions and 18 derivative rows are listed below.
- Accepted by SEC: 04 Nov 2026, 18:06.
William Todd Horich - 02 Nov 2026 Form 4 Insider Report for Supernus, Inc. (INDV)
- Reporting relationship
- SVP, Chief Commercial Officer
- Issuer ticker
- INDV
- Reported as of
- 02 Nov 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2026, 18:06:11 UTC
- Prior SEC filing
- 02 Nov 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Timothy C. Dec, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
William Todd Horich filed Form 4 for Supernus, Inc. (INDV) on 04 Nov 2026.
Change
- Previous filing in this sequence was filed on 02 Nov 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002117599
Primary reporting owner
Horich William Todd
- Relationship
- SVP, Chief Commercial Officer
- Address
- C/O SUPERNUS, INC., 9715 KEY WEST AVENUE, ROCKVILLE
- Signature
- /s/ Timothy C. Dec, as attorney-in-fact
- Signature date
- 04 Nov 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INDV
transaction
Derivative
Employee Stock Option (right to buy)
Other
- Transaction value
- Shares
- +20,021
- Change %
- Price
- $0.000000*
- Shares after
- 20,021
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,021
- Exercise price
- $25.59
- Footnotes
- F1, F2
INDV
transaction
Derivative
Employee Stock Option (right to buy)
Other
- Transaction value
- Shares
- +21,561
- Change %
- Price
- $0.000000*
- Shares after
- 21,561
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 21,561
- Exercise price
- $23.87
- Footnotes
- F1, F2
INDV
transaction
Derivative
Employee Stock Option (right to buy)
Other
- Transaction value
- Shares
- +26,181
- Change %
- Price
- $0.000000*
- Shares after
- 26,181
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 26,181
- Exercise price
- $19.23
- Footnotes
- F1, F2
INDV
transaction
Derivative
Employee Stock Option (right to buy)
Other
- Transaction value
- Shares
- +27,721
- Change %
- Price
- $0.000000*
- Shares after
- 27,721
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,721
- Exercise price
- $20.91
- Footnotes
- F1, F2
INDV
transaction
Derivative
Employee Stock Option (right to buy)
Other
- Transaction value
- Shares
- +30,802
- Change %
- Price
- $0.000000*
- Shares after
- 30,802
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,802
- Exercise price
- $25.07
- Footnotes
- F1, F2
INDV
transaction
Derivative
Employee Stock Option (right to buy)
Other
- Transaction value
- Shares
- +38,502
- Change %
- Price
- $0.000000*
- Shares after
- 38,502
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 38,502
- Exercise price
- $18.15
- Footnotes
- F1, F2
INDV
transaction
Derivative
Employee Stock Option (right to buy)
Other
- Transaction value
- Shares
- +20,791
- Change %
- Price
- $0.000000*
- Shares after
- 20,791
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,791
- Exercise price
- $32.60
- Footnotes
- F1, F2
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +9,625
- Change %
- Price
- $0.000000*
- Shares after
- 9,625
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,625
- Exercise price
- $0.000000
- Footnotes
- F1, F3
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +3,850
- Change %
- Price
- $0.000000*
- Shares after
- 3,850
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,850
- Exercise price
- $0.000000
- Footnotes
- F1, F4
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +5,197
- Change %
- Price
- $0.000000*
- Shares after
- 5,197
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,197
- Exercise price
- $0.000000
- Footnotes
- F1, F5
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +4,620
- Change %
- Price
- $0.000000*
- Shares after
- 4,620
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,620
- Exercise price
- $0.000000
- Footnotes
- F1, F6
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +154,010
- Change %
- Price
- $0.000000*
- Shares after
- 154,010
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 154,010
- Exercise price
- $0.000000
- Footnotes
- F1, F7
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +1,155
- Change %
- Price
- $0.000000*
- Shares after
- 1,155
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,155
- Exercise price
- $0.000000
- Footnotes
- F1, F8
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +2,695
- Change %
- Price
- $0.000000*
- Shares after
- 2,695
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,695
- Exercise price
- $0.000000
- Footnotes
- F1, F8
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +3,850
- Change %
- Price
- $0.000000*
- Shares after
- 3,850
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,850
- Exercise price
- $0.000000
- Footnotes
- F1, F8
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +808
- Change %
- Price
- $0.000000*
- Shares after
- 808
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 808
- Exercise price
- $0.000000
- Footnotes
- F1, F9
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +1,886
- Change %
- Price
- $0.000000*
- Shares after
- 1,886
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,886
- Exercise price
- $0.000000
- Footnotes
- F1, F9
INDV
transaction
Derivative
Restricted Stock Units
Other
- Transaction value
- Shares
- +2,695
- Change %
- Price
- $0.000000*
- Shares after
- 2,695
- Date
- 02 Nov 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,695
- Exercise price
- $0.000000
- Footnotes
- F1, F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards were converted into time-vesting restricted stock units.
Footnote F2
The option vests in four equal annual installments beginning on the specified date.
Footnote F3
These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
Footnote F4
These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.
Footnote F5
These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.
Footnote F6
These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.
Footnote F7
These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in five installments. 40% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 15% of the RSUs vest upon the three-year anniversary of the Closing. 15% of the RSUs vest upon the four-year anniversary of the Closing.
Footnote F8
These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2026.
Footnote F9
These restricted stock units are settled in common stock upon vesting, which occurs on December 31, 2028.